<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Nat Commun</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id>
<journal-title-group>
<journal-title>Nature Communications</journal-title>
</journal-title-group>
<issn pub-type="epub">2041-1723</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32493979</article-id>
<article-id pub-id-type="pmc">7271128</article-id>
<article-id pub-id-type="publisher-id">16629</article-id>
<article-id pub-id-type="doi">10.1038/s41467-020-16629-3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Polyamine regulation of ion channel assembly and implications for nicotinic acetylcholine receptor pharmacology</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dhara</surname>
<given-names>Madhurima</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matta</surname>
<given-names>Jose A.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lei</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Knowland</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Hong</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gu</surname>
<given-names>Shenyan</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4985-0164</contrib-id>
<name>
<surname>Bredt</surname>
<given-names>David S.</given-names>
</name>
<address>
<email>dbredt@its.jnj.com</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1">Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson and Johnson, 3210 Merryfield Row, San Diego, CA 92121 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>3</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>3</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>2799</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>1</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Small molecule polyamines are abundant in all life forms and participate in diverse aspects of cell growth and differentiation. Spermidine/spermine acetyltransferase (SAT1) is the rate-limiting enzyme in polyamine catabolism and a primary genetic risk factor for suicidality. Here, using genome-wide screening, we find that SAT1 selectively controls nicotinic acetylcholine receptor (nAChR) biogenesis. SAT1 specifically augments assembly of nAChRs containing α7 or α4β2, but not α6 subunits. Polyamines are classically studied as regulators of ion channel gating that engage the nAChR channel pore. In contrast, we find polyamine effects on assembly involve the nAChR cytosolic loop. Neurological studies link brain polyamines with neurodegenerative conditions. Our pharmacological and transgenic animal studies find that reducing polyamines enhances cortical neuron nAChR expression and augments nicotine-mediated neuroprotection. Taken together, we describe a most unexpected role for polyamines in regulating ion channel assembly, which provides a new avenue for nAChR neuropharmacology.</p>
</abstract>
<abstract abstract-type="web-summary" id="Abs2">
<p id="Par2">Small molecule polyamines participate in diverse aspects of cell growth and differentiation and are known to regulate ion channel gating. Here authors reveal that cellular polyamines control nicotinic acetylcholine receptor (nAChR) biogenesis, and either catabolic degradation or inhibition of polyamine production augments nAChR assembly.</p>
</abstract>
<kwd-group kwd-group-type="npg-subject">
<title>Subject terms</title>
<kwd>Ion channels</kwd>
<kwd>Molecular biophysics</kwd>
<kwd>Protein folding</kwd>
<kwd>Cell death in the nervous system</kwd>
<kwd>Cellular neuroscience</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p id="Par3">Neuronal nicotinic acetylcholine receptor (nAChR) ion channels mediate behavioral, cognitive and autonomic effects of acetylcholine and addictive properties of nicotine<sup><xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR6">6</xref></sup>. The nAChR family comprises nine alpha (α2-10) and three beta (β2-4) subunits that combine to form an array of pentameric cation channels throughout the brain and peripheral nervous systems. The major nACh receptors in brain are α7 homomers, α4β2 heteromers, and α6-containing heteromers. These receptors are targets of numerous approved and experimental medicines for diverse conditions including Alzheimer’s disease, Parkinson’s disease, and neuropathic pain<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
<p id="Par4">Whereas nAChRs are compelling drug targets, progress is hampered because most receptor subtypes do not functionally express in the non-neuronal cell lines used for screening<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. We previously identified NACHO, a four-pass transmembrane protein that serves as a client-specific chaperone for assembly of most neuronal nAChRs<sup><xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref></sup>. In brain, NACHO is essential for function of α7 receptors, and additional proteins, Ric-3<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and certain Bcl-2 family members<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, synergize with NACHO to enhance α7 assembly and surface trafficking. NACHO also promotes assembly of α4β2 receptors, though Ric-3 and Bcl-2 proteins have minimal impact on α4β2.</p>
<p id="Par5">Here, we sought factors that conspire with NACHO to enhance function of α4β2 receptors, the most abundant nAChR subtype in brain. These neuronal α4β2 receptors mediate diverse physiological actions of acetylcholine and underlie nicotine dependence<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Genome-wide cDNA screening for protein enhancers of α4β2 function identified, quite surprisingly, a single standout clone that encodes spermidine/spermine acetyltransferase (SAT1), the rate limiting enzyme for polyamine catabolism. By degrading polyamines, SAT1 promotes α4β2 function to an even greater extent than does NACHO.</p>
<p id="Par6">Polyamines are abundant polycations, including spermidine and spermine, that play multiple roles in cell growth, differentiation and survival<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. The interplay between their synthesis by ornithine decarboxylase-1 (ODC1) and their degradation by SAT1 controls polyamine levels. ODC1 is amongst the most dynamically regulated of all human proteins, and ODC1 is a drug target in oncology and infectious disease<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. SAT1 transcription is also highly-regulated, and its acetylation of polyamines promotes their cellular export<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Interestingly, numerous large genomic studies link polymorphisms in SAT1 with suicidal behavior<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. In neurons, polyamines play important roles in synaptic transmission by conferring inward rectification to certain potassium channels, AMPA receptors and nACh receptors<sup><xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR22">22</xref></sup>. Polyamines also participate in the pathogenesis of neurodegenerative disorders<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> and the excitotoxicity associated with cerebral ischemia<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p>
<p id="Par7">We now find that polyamines also control assembly of neuronal α4β2 and α7 receptors. By contrast, polyamines do not modulate assembly of α6β4 nAChRs, AMPA receptors or any other ion channel tested. Whereas polyamines classically regulate channel gating by occluding the ion pore, polyamine regulation of nAChR assembly instead relies on negatively charged residues within the α4 or α7 cytosolic loop. Neuropharmacology studies using wild-type and NACHO knockout mice show that lowering polyamine levels selectively upregulates cerebrocortical α4β2 and α7 levels and enhances the neuroprotective properties of nicotine. These studies identify an unexpected role for polyamines in controlling ion channel biogenesis and suggest new strategies in neuropharmacology.</p>
</sec>
<sec id="Sec2" sec-type="results">
<title>Results</title>
<sec id="Sec3">
<title>Genome-wide screening identifies SAT1 as an enhancer of nAChR</title>
<p id="Par8">To identify novel regulators of α4β2 receptors, we co-transfected human embryonic kidney 293T cells (HEK293T) with plasmids encoding α4 and β2 subunits along with individual constructs from a 5943-cDNA clone library from the Broad Institute<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Transfected cells were stimulated with nicotine (100 µM) and intracellular Ca<sup>2+</sup> was quantified with a fluorescence imaging plate reader (FLIPR) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>). As previously shown<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, α4β2 alone produced a small nicotine-evoked Ca<sup>2+</sup> signal, and co-transfection with NACHO significantly enhanced this (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>). High throughput screening identified a single clone that profoundly augmented the nicotine-induced Ca<sup>2+</sup> response—to levels much higher than NACHO; this clone encoded spermidine/spermine N1-acetyltransferase (SAT1) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>High throughput cDNA screening for enhancers of α4β2 function identifies SAT1.</title><p><bold>a</bold> HEK293T cells in 384-well plates were co-transfected with α4-expressing and β2-expressing plasmids along with an individual cDNA (black traces) from a human ORF collection (Broad Institute). Cells were stimulated with 100 μM nicotine (Nic). The highest response occurred in the well containing SAT1 (red trace) and was twice the α4β2 + NACHO response (gray trace), which served as positive control. <bold>b</bold> Quantification (mean ± SD) of maximum Ca<sup>2+</sup> signal upon agonist stimulation from HEK293T cells transfected as indicated (<italic>n</italic> = 6). Co-transfection of SAT1 significantly enhances Ca<sup>2+</sup> signal in α4β2 (<italic>p</italic> &lt; 1e<sup>−4</sup>), α4β2+NACHO (<italic>p</italic> &lt; 1e<sup>−4</sup>) and α7+NACHO (<italic>p</italic> = 0.002) cells. For all α6β4 conditions, cells were co-transfected with plasmids encoding accessories BARP and SULT2B1<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. <bold>c</bold> Representative whole-cell current responses elicited from HEK cells co-transfected with GFP and cDNAs as indicated. <bold>d</bold> Summary graphs of agonist-evoked peak currents (mean ± SEM) from HEK293T cells transfected with indicated cDNA combinations. Similar to maximum Ca<sup>2+</sup> signal, co-transfection of SAT1 boosts evoked currents mediated by α4β2 (<italic>p</italic> &lt; 1e<sup>−4</sup>), α4β2+NACHO (<italic>p</italic> &lt; 1e<sup>−4</sup>), α7+NACHO (<italic>p</italic> &lt; 1e<sup>−4</sup>) but not α6β4 (<italic>p</italic> = 0.98) or 5-HT<sub>3</sub>A (<italic>p</italic> = 0.73). Numbers indicate number of transfected cells that were analyzed and were pooled from three independent cultures. **p &lt; 0.01, ***<italic>p</italic> &lt; 0.001, One-way ANOVA between the groups for α4β2 and α7. Mann–Whitney <italic>U</italic> test versus control for α6β4 and 5-HT<sub>3</sub>A. Source data for panel <bold>b</bold> and <bold>d</bold> are provided as a Source Data file.</p></caption><graphic id="d30e476" xlink:href="41467_2020_16629_Fig1_HTML"></graphic></fig></p>
<p id="Par9">We evaluated the effect of SAT1 on other nAChRs and other Cys-loop receptors both by FLIPR and electrophysiology. Consistent with our screening results, SAT1 dramatically increased ACh-evoked currents from α4β2 (Fig. <xref ref-type="fig" rid="Fig1">1c, d</xref>). SAT1 also synergized with NACHO to further enhance the α4β2-mediated Ca<sup>2+</sup> influx (Fig. <xref ref-type="fig" rid="Fig1">1b, d</xref>), suggesting that SAT1 and NACHO employ different mechanisms. Whereas SAT1 alone did not rescue homomeric α7 function, SAT1 powerfully synergized with NACHO to increase α7 mediated currents (Fig. <xref ref-type="fig" rid="Fig1">1b–d</xref>). In contrast, SAT1 had no significant effect on α6β4 or 5-HT3A receptor function (Fig. <xref ref-type="fig" rid="Fig1">1b–d</xref>).</p>
<p id="Par10">SAT1, a small cytosolic protein, is the rate-limiting enzyme for polyamine catabolism (Supplementary Fig. <xref ref-type="media" rid="MOESM1">1</xref>). Together with polyamine oxidase, SAT1 acetylates higher-order polyamines converting them to inactive forms that are transported out of cells<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. By lowering polyamine levels, SAT1 effects on nAChRs could reflect disinhibition, as polyamines can negatively affect nAChR gating<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. This seemed unlikely for two reasons, First, α6-containing nAChRs are more sensitive to polyamine inhibition of gating than are α7<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> whereas we find the opposite sensitivity to SAT1 in our functional assays (Fig. <xref ref-type="fig" rid="Fig1">1b–d</xref>). Second, polyamines do not block nAChRs at the hyperpolarized membrane potentials we used for patch clamp studies<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. As an alternative mechanism, we asked whether SAT1 increases nAChR surface expression. To assess this, we utilized extracellular HA-tagged subunits that allow detection of surface receptors without disrupting channel function<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Strikingly, SAT1 boosted surface levels of both α4β2 and α7 (Fig. <xref ref-type="fig" rid="Fig2">2a, b</xref>). SAT1 also augmented surface trafficking atop the effects of the α7 protein chaperones Ric-3, Bcl-X<sub>L</sub>, and Mcl-1, as well as the α7 chemical chaperone/orthosteric antagonist, methyllycaconitine (MLA) (Supplementary Fig. <xref ref-type="media" rid="MOESM1">2a, b</xref>) implying that receptor upregulation by SAT1 involves a mechanism distinct from any previously described.<fig id="Fig2"><label>Fig. 2</label><caption><title>By catalyzing polyamines, SAT1 promotes surface expression and assembly of nAChRs.</title><p><bold>a</bold> HEK293T cells were co-transfected with cDNAs encoding HA-tagged receptors and other plasmids as indicated. Some cells were pre-treated for 24 h with 1 mM DFMO. Immunofluorescent labeling of the extracellular HA-tag in unpermeabilized cells enabled visualization (red) of surface receptors. Scale bar = 50 μm. <bold>b</bold> Summary graph quantifies surface HA-labeling (<italic>n</italic> = 6). Co-transfection with wildtype SAT1, not its mutant version, promotes surface expression of α4β2 (<italic>p</italic> &lt; 1e<sup>−4</sup>), α4β2+NACHO (<italic>p</italic> &lt; 1e<sup>−4</sup>) and α7+NACHO (<italic>p</italic> &lt; 1e<sup>−4</sup>) but not 5-HT<sub>3</sub>A (<italic>p</italic> = 0.84). Pre-treating cells with DFMO show comparable results. <bold>c</bold> Quantification of [<sup>3</sup>H]epibatidine binding to HEK293T cell membranes transfected and pre-treated with DFMO where indicated (<italic>n</italic> = 8). Similar to surface HA-labeling, SAT1 co-transfection and DFMO preincubation increase radioligand binding to α4β2 (<italic>p</italic> &lt; 1e<sup>−4</sup>) and to α7+NACHO (<italic>p</italic> &lt; 1e<sup>−4</sup>). <bold>d</bold> Quantification of surface α4β2-HA or α7-HA in HEK293T cells transfected with SAT1 and pretreated with BenSpm (<italic>n</italic> = 7) or spermine (<italic>n</italic> = 6) as indicted. Only BenSpm occludes SAT1 mediated increase of surface α4β2 (<italic>p</italic> = 1e<sup>−3</sup>) or α7 (<italic>p</italic> = 1e<sup>−3</sup>). Data in <bold>b</bold>–<bold>d</bold> are presented as mean ± SD. **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, One-way ANOVA between the groups. Source data for panel <bold>b</bold>–<bold>d</bold> are provided as a Source Data file.</p></caption><graphic id="d30e639" xlink:href="41467_2020_16629_Fig2_HTML"></graphic></fig></p>
</sec>
<sec id="Sec4">
<title>SAT1 promotes assembly of nAChRs by catalyzing polyamines</title>
<p id="Par11">To determine whether effects on nAChRs involve the catalytic activity of SAT1, we constructed a Tyr140Phe mutant that abolishes SAT1 enzyme activity<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. This mutant SAT1 (mutSAT1) did not change surface expression of α4β2 or α7 receptors in the presence or absence of NACHO (Fig. <xref ref-type="fig" rid="Fig2">2a, b</xref>). Ornithine decarboxylase 1 (ODC1) is the rate-limiting enzyme for polyamine synthesis (Supplementary Fig. <xref ref-type="media" rid="MOESM1">1</xref>), and difluoromethylornithine (DFMO) is an ODC1 active site inhibitor<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> that depletes cellular polyamines<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Like SAT1 co-transfection, DFMO pretreatment augmented surface expression of α4β2 and synergized with NACHO to further enhance α4β2 and α7 surface receptors (Fig. <xref ref-type="fig" rid="Fig2">2a, b</xref>). Pursuing the opposite tact, we found that co-transfection with the polyamine biosynthetic enzymes ODC1 and adenosylmethionine decarboxylase 1 (AMD1) diminished nAChR surface staining (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3a, b</xref>). Neither catabolic (SAT1 co-transfection or DFMO pretreatment) nor anabolic (ODC1 and AMD1 co-transfection) polyamine manipulations affected surface expression of the 5-HT3A receptor (Fig. <xref ref-type="fig" rid="Fig2">2a, b</xref>; Supplementary Fig. <xref ref-type="media" rid="MOESM1">3a, b</xref>).</p>
<p id="Par12">We asked next whether polyamines influence nAChR assembly, which can be probed with orthosteric ligands, such as [<sup>3</sup>H]epibatidine, that only bind at the interface between folded subunits<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Remarkably, either SAT1 or DFMO enhanced [<sup>3</sup>H]epibatidine binding to α4β2 or α7 receptors (Fig. <xref ref-type="fig" rid="Fig2">2c</xref>). Furthermore, ODC1 and AMD1 reduced ligand binding to these receptors (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3c</xref>).</p>
<p id="Par13">N1,N11-bis-(ethyl)-norspermine (BenSpm) is a stable polyamine analog and SAT1 inhibitor<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>, and treatment of cells with 10 µM BenSpm specifically reversed the effects of SAT1 on nAChR surface expression (Fig. <xref ref-type="fig" rid="Fig2">2d</xref>). By contrast, incubating cells with spermine, which does not penetrate cells and is rapidly degraded by SAT1, did not affect nAChR surface expression (Fig. <xref ref-type="fig" rid="Fig2">2d</xref>). Taken together, we find that polyamines, independent of their established role in ion channel gating, enhance nAChR function by promoting surface expression and augmenting receptor assembly.</p>
</sec>
<sec id="Sec5">
<title>Polyamines regulate nAChRs assembly via their cytosolic loop</title>
<p id="Par14">Certain neuronal nAChRs display blunted ion flow at depolarized potentials. This inward rectification is mediated by polyamine binding to pore-lining glutamate residues in the nAChR transmembrane domain 2 (TM2) corresponding to Glu247 in α4<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. It was previously shown that mutating this acidic residue to alanine (α4<sub>E247A</sub>) relieves polyamine block of α4β2 channels in <italic>Xenopus laevis</italic> oocytes<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Loss of negative charge in the α4<sub>E247A</sub> also reduces calcium permeability through the mutant receptor. Accordingly, we found that a E247A α4 mutant (Fig. <xref ref-type="fig" rid="Fig3">3a</xref>) co-transfected with β2 evinced minimal nicotine-evoked Ca<sup>2+</sup> influx in HEK293T cells (Fig. <xref ref-type="fig" rid="Fig3">3b</xref>), and this was unaffected by preincubation with DFMO or co-transfection with SAT1. By contrast, DFMO or SAT1 enhanced surface expression of α4<sub>E247A</sub>/β2 similar to wildtype α4β2 (Fig. <xref ref-type="fig" rid="Fig3">3c</xref>, d). These data establish distinct mechanisms for polyamine regulation of nAChR gating and trafficking.<fig id="Fig3"><label>Fig. 3</label><caption><title>Polyamine regulation of α4β2 assembly is mechanistically distinct from channel gating or agonist binding.</title><p><bold>a</bold> Cartoon depicting α4 nAChR subunit. Enlarged view (bottom) highlights Glu247 in α4 TM2 critical for polyamine regulation of gating and Ca<sup>2+</sup>-permeability. Yellow spheres represent pore diameter &gt;2.8 Å, blue spheres &gt;5.6 Å. (PDB: 5KXI) <bold>b</bold> Quantification shows wild-type α4β2-mediated peak nicotine-evoked Ca<sup>2+</sup> is enhanced in cells co-transfected with SAT1 (<italic>p</italic> &lt; 1e<sup>−4</sup>) and pre-treated with DFMO (<italic>p</italic> &lt; 1e<sup>−4</sup>). α4E<sub>247</sub>Aβ2 transfected cells have reduced nicotine-evoked Ca<sup>2+</sup> (<italic>p</italic> = 0.01), which is not changed with SAT1 or DFMO (<italic>n</italic> = 6). <bold>c</bold> Summary graph (<italic>n</italic> = 6) and <bold>d</bold>. representative images of fluorescent anti-HA labeling of non-permeabilized HEK293T cells transfected as indicated and pretreated with DFMO where noted (Scale bar = 50 μm). Quantifications are displayed as mean ± SD. ***<italic>p</italic> &lt; 0.001, One-way ANOVA between the groups. <bold>e</bold> Cartoon depicting α4 nAChR subunit. Enlarged view (top) highlights Trp156 in α4 that forms a cation-π interaction with nicotine (yellow). <bold>f</bold> Nicotine-evoked Ca<sup>2+</sup> from wild-type α4β2 (black trace) or mutant α4W<sub>156</sub>Aβ2 (blue trace) (PDB: 5KXI). <bold>g</bold> Binding of [<sup>3</sup>H]epibatidine (10 nM) to HEK293T cell membranes is significantly reduced (<italic>p</italic> &lt; 1e<sup>−5</sup>) in mutant α4W<sub>156</sub>Aβ2 co-transfected group compared with wild-type α4β2 (<italic>n</italic> = 8). <bold>h</bold> Fluorescent anti-HA labeling of non-permeabilized HEK293T cells transfected as indicated. Scale bar = 50 μm. <bold>i</bold> Quantification of surface labeling from <bold>h</bold> (<italic>n</italic> = 6). SAT1 enhances surface labeling of both α4β2 (<italic>p</italic> = 0.002) and α4W<sub>156</sub>Aβ2 (<italic>p</italic> = 0.002) receptors. NACHO cDNA was included for all receptor transfections in <bold>f</bold>–<bold>i</bold>. Quantifications are means ± SD. **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, Mann–Whitney <italic>U</italic> test versus control was used for data shown in panel <bold>g</bold>, <bold>i</bold>. Source data for panels <bold>b</bold>, <bold>c</bold>, <bold>g</bold> and <bold>i</bold> are provided as a Source Data file.</p></caption><graphic id="d30e898" xlink:href="41467_2020_16629_Fig3_HTML"></graphic></fig></p>
<p id="Par15">We next mutated Trp156 (Fig. <xref ref-type="fig" rid="Fig3">3e</xref>) in the α4 ligand-binding domain<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. As expected, when co-transfected with β2, this α4<sub>W156A</sub> mutant was functionally inactive and did not bind to [<sup>3</sup>H]epibatidine (Fig. <xref ref-type="fig" rid="Fig3">3f, g</xref>). By contrast, this mutant showed typical surface staining enhancement upon co-transfection with SAT1 cDNA (Fig. <xref ref-type="fig" rid="Fig3">3h, i</xref>) indicating that polyamine regulation is independent of agonist binding.</p>
<p id="Par16">To identify nAChR regions responsible for regulation, we generated chimeras of α4 with α6, as surface expression of the latter is not regulated by polyamines (Fig. <xref ref-type="fig" rid="Fig4">4a</xref>). We co-transfected these α4/α6 chimeras with β4 and quantified both receptor surface expression and nicotine-evoked Ca<sup>2+</sup> signaling (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). SAT1 co-transfection enhanced a chimera containing the α6 N-terminal and α4 C-terminal region but did not affect the converse chimera (Fig. <xref ref-type="fig" rid="Fig4">4a–c</xref>), which implies that polyamine regulation involves the channel or the large cytosolic loop, which occurs between TM3 and TM4. We next constructed a pair of chimeras that swapped only this cytosolic loop. Quantification of receptor surface expression and function showed that the α4 TM3-TM4 cytosolic loop is both necessary and sufficient for SAT1-dependent regulation of these nAChRs (Supplementary Fig. <xref ref-type="media" rid="MOESM1">4</xref>). Similarly, exchanging the TM3-TM4 loop of homomeric α7 receptor with that of α6 (Supplementary Fig. <xref ref-type="media" rid="MOESM1">4d</xref>) abolished SAT1-mediated upregulation of alpha-bungarotoxin (α-Bgt) binding sites on α7 (Supplementary Fig. <xref ref-type="media" rid="MOESM1">4e, f</xref>), which demonstrates that the intracellular loop determines polyamine-regulation of both α4 and α7 nAChR assembly.<fig id="Fig4"><label>Fig. 4</label><caption><title>The nAChR TM3-TM4 cytosolic loop determines regulation by SAT1.</title><p><bold>a</bold> Schematics of chimeric α4-α6 constructs. <bold>b</bold> Fluorescent anti-HA labeling of non-permeabilized HEK293T cells co-transfected with cDNAs encoding α6, α4, α4-α6 chimeric constructs and extracellular HA-tagged β4 with or without SAT1 as indicated. All cDNA combinations contained BARP and SULT2B1. Scale bar = 50 μm <bold>c</bold>. Agonist-evoked Ca<sup>2+</sup> traces from HEK293T transfected as indicated. The α4 cytosolic loop domain is necessary and sufficient for SAT1-mediated regulation for all chimeras. Note that data in <bold>b</bold> and <bold>c</bold> are quantified in Supplementary Figs. <xref ref-type="media" rid="MOESM1">4b, c</xref>.</p></caption><graphic id="d30e976" xlink:href="41467_2020_16629_Fig4_HTML"></graphic></fig></p>
<p id="Par17">Previous studies noted that, within the T3-TM4 loop, a subdomain proximal to TM4 contains conserved positively and negatively charged residues<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Interestingly, we observed certain negatively charged residues (Glu and Asp) in this subdomain that are conserved between α7 and α4 but diverge in α6 to uncharged Asn (Supplementary Fig. <xref ref-type="media" rid="MOESM1">5a, b</xref>)<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Mutating those Glu and Asp to Ala in α7 (E<sub>438</sub>A or D<sub>451</sub>A) and α4 (E<sub>569</sub>A or D<sub>582</sub>A) blocked SAT1-mediated upregulation of α7 assembly (Supplementary Fig. <xref ref-type="media" rid="MOESM1">5c, d</xref>) and α4β2 surface expression (Supplementary Fig. <xref ref-type="media" rid="MOESM1">5</xref> e, f). By contrast, these mutations did not blunt effects of Ric-3 on α7 or NACHO on α4β2. Replacing the corresponding Asn residues (N<sub>434</sub> or N<sub>447</sub>) to Glu within the α6 cytosolic loop conferred moderate but significant SAT1 and DFMO sensitivity to α6β4 receptors (Supplementary Fig. <xref ref-type="media" rid="MOESM1">5g, h</xref>). These experiments identify negatively charged residues within the TM3-TM4 cytosolic loop that can mediate polyamine regulation of nAChR assembly and surface expression. Future studies are needed to fully elucidate these mechanisms.</p>
</sec>
<sec id="Sec6">
<title>Polyamines regulate nAChR gating and assembly independently</title>
<p id="Par18">To further distinguish mechanisms for polyamine control of nAChR assembly and gating, we compared effects of the membrane-permeant polyamine analog BenSpm with philanthotoxin-343 (PhTx-343), which cannot enter cells and engages the channel pore via a long polyamine tail<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. Neither BenSpm nor PhTx-343 preincubation changed basal surface levels of α4β2. Whereas BenSpm abrogated SAT1-mediated enhancement of surface α4β2, PhTx-343 did not (Fig. <xref ref-type="fig" rid="Fig5">5a</xref>, b). By contrast, both BenSpm and PhTx-343 preincubation abolished nicotine-evoked Ca<sup>2+</sup> with or without SAT1 co-transfection (Fig. <xref ref-type="fig" rid="Fig5">5c</xref>). These data demonstrate that only cell-permeant polyamines can control of nAChR surface trafficking.<fig id="Fig5"><label>Fig. 5</label><caption><title>Polyamine analogs regulate nAChR gating and assembly by distinct mechanisms.</title><p><bold>a</bold> Fluorescent anti-HA labeling of non-permeabilized HEK293T cells transfected with cDNAs encoding extracellular HA-tagged β2 and α4 with or without SAT1. Scale bar = 50 μm<bold>. b</bold> Quantification of surface staining for α4β2 receptors with or without SAT1 and BenSpm or PhTx343 pre-treatment (<italic>n</italic> = 6). BenSpm occluded the SAT1-enhanced receptor surface expression (<italic>p</italic> &lt; 1e<sup>−4</sup>) but PhTx343 had no effect (<italic>p</italic> = 0.86). <bold>c</bold> Nicotine-evoked Ca<sup>2+</sup> signal was fully blocked by both BenSpm or PhTx343 (<italic>p</italic> &lt; 1e<sup>−4</sup>) (<italic>n</italic> = 6). <bold>d</bold> Schematics of chimeric constructs of α4-α6. <bold>e</bold> Normalized anti-HA surface expression from cells transfected and treated with BenSpm or PhTx343 as indicated (<italic>n</italic> = 5). Only BenSpm occluded SAT1-mediated enhancement of surface receptor expression of α4β4 (<italic>p</italic> &lt; 1e<sup>−4</sup>), α6NT/α4β4 (<italic>p</italic> &lt; 1e<sup>−4</sup>) and α6/α4-loopβ4 (<italic>p</italic> &lt; 1e<sup>−4</sup>). Both SAT1 and BenSpm effects on receptor surface expression required the α4 cytosolic loop. <bold>f</bold> Both BenSpm and PhTx343 fully inhibited nicotine-evoked Ca<sup>2+</sup> in all receptor combinations. All cDNA combinations included BARP and SULT2B1. Quantifications are displayed as mean ± SD. ***<italic>p</italic> &lt; 0.001, One-way ANOVA between the groups was used for panels <bold>b</bold>, <bold>c</bold> and <bold>e</bold>. Comprehensive dose-response studies are in Supplementary Fig. <xref ref-type="media" rid="MOESM1">5</xref>. Source data for panel <bold>b</bold>, <bold>c</bold> and <bold>e</bold> are provided as a Source Data file.</p></caption><graphic id="d30e1143" xlink:href="41467_2020_16629_Fig5_HTML"></graphic></fig></p>
<p id="Par19">To more completely elucidate these mechanisms, we compared effects of BenSpm and PhTx-343 on α4-containing and α6-containing receptors, as SAT1 regulates trafficking of α4β4 but not α6β4 (Fig. <xref ref-type="fig" rid="Fig4">4b</xref>). As expected, pre-treatment with BenSpm, but not PhTx-343, reversed SAT1-mediated enhancement of α4β4 surface expression and neither had effect on α6β4 surface expression (Fig. <xref ref-type="fig" rid="Fig5">5d</xref>, e). By contrast, both BenSpm and PhTx-343 application abolished nicotine-evoked Ca<sup>2+</sup> signaling from either α4β4 or α6β4 (Fig. <xref ref-type="fig" rid="Fig5">5f</xref>).</p>
<p id="Par20">We next evaluated effects of BenSpm and PhTx-343 on the α6/α4 chimeric constructs, which swap the extracellular N-terminal or TM3-TM4 cytosolic loop domains. As predicted, the α4 cytosolic loop was necessary and sufficient for BenSpm pre-treatment to reverse SAT1-mediated enhancement of receptor surface expression, and PhTx-343 did not alter surface expression for any chimera (Fig. <xref ref-type="fig" rid="Fig5">5e</xref> and Supplementary Fig. <xref ref-type="media" rid="MOESM1">6d, e</xref>). By contrast, acute application of either BenSpm or PhTx-343 blocked nicotine-evoked Ca<sup>2+</sup>-signaling from all receptor chimeras in a concentration-dependent manner (Fig. <xref ref-type="fig" rid="Fig5">5f</xref>, Supplementary Fig. <xref ref-type="media" rid="MOESM1">6a–c</xref>). These molecular biological and pharmacological studies establish distinct mechanisms and protein domains for polyamine control of nAChR trafficking and gating.</p>
</sec>
<sec id="Sec7">
<title>Polyamines regulate assembly of neuronal nAChRs</title>
<p id="Par21">We next explored whether polyamines upregulate endogenous nAChRs in neurons. Accordingly, we treated cultured rat cortical neurons with DFMO and quantified α7 nAChR surface expression with fluorescent α-Bgt. As a positive control, we incubated neurons with 100 μM nicotine<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> and found a significant increase in surface α-Bgt binding sites (Fig. <xref ref-type="fig" rid="Fig6">6a, b</xref>). Similarly, treating neurons with DFMO robustly increased surface α-Bgt binding (Fig. <xref ref-type="fig" rid="Fig6">6a, b</xref>). By contrast, neither DFMO nor nicotine altered surface expression of the AMPA-type glutamate receptor subunit GluA1 (Fig. <xref ref-type="fig" rid="Fig6">6a, b</xref>). Preincubating neurons with DFMO also increased the nicotine-evoked Ca<sup>2+</sup> signal (Fig. <xref ref-type="fig" rid="Fig6">6c</xref>), an effect that was comparable to the enhancement seen following nicotine pretreatment. These nicotine-evoked Ca<sup>2+</sup> responses reflect α7 activity, as they require the α7-specific positive allosteric modulator (PAM) PNU-12059615<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and were abolished by the α7-specific inhibitor α-Bgt (Fig. <xref ref-type="fig" rid="Fig6">6c</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><title>DFMO enhances both neuronal nAChRs and nicotine-mediated neuroprotection.</title><p><bold>a</bold> Fluorescent labeling of non-permeabilized rat cortical neurons (DIV 20) shows upregulation of endogenous α-Bgt674 labeling in neurons pre-treated for six days with DFMO (5 mM) or nicotine (Nic; 100 μM) as indicated. Surface-labeling for α7 used α-Bgt647 (red) and insets (white squares) depict magnifications that include DAPI (blue). Double-labeling with α-GluA1 (green) served as control. <bold>b</bold> Quantification of surface α-Bgt647 shows increased staining with both DFMO and Nic (<italic>p</italic> &lt; 1e<sup>−4</sup>), but no change was observed in surface GluA1 staining (<italic>p</italic> = 0.9). <bold>c</bold> Summary graph showing nicotine (100 μM) + PNU-12059615- (10 µM) evoked Ca<sup>2+</sup> from rat cortical neurons (DIV 13) increases when pre-treated for six days with DFMO (<italic>p</italic> = 0.002) or nicotine (<italic>p</italic> = 0.0004). Responses were blocked by α-Bgt (0.5 μM). Data shown in B and C were averaged from 3 independent experiments each containing 6 independent samples. <bold>d</bold> Quantification of [<sup>3</sup>H]epibatidine (10 nM) and [<sup>3</sup>H]flunitrazepam (50 nM) binding to membranes from neurons pre-treated with DFMO or transduced with SAT1 show selective increase in [<sup>3</sup>H]epibatidine binding (<italic>p</italic> &lt; 1e<sup>−4</sup>). One-way ANOVA compared to control. Neurons transduced with lentivirus expressing α4 and β2 showed much higher levels of [<sup>3</sup>H]epibatidine binding (hatched bars) (<italic>p</italic> &lt; 1e<sup>−4</sup>, compared to un-transduced control), and these were further enhanced (<italic>p</italic> &lt; 1e<sup>−4</sup>) with DFMO treatment (<italic>n</italic> = 8). <bold>e</bold> Acute application of nicotine (gray bars) partially reduced glutamate-mediated cell death (left panel) and mobilization of CytC (right panel). Pre-treating neurons for six days with DFMO (green, 5 mM) enhanced nicotine-mediated cell survival (<italic>p</italic> = 0.006) and decreased CytC mobilization (<italic>p</italic> = 0.001). Nicotine (orange, 100 μM) pre-treatment similarly enhanced nicotine-mediated neuroprotection. Data averaged from 3 independent experiments each containing 6 independent samples. Quantifications are displayed as mean ± SD. **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, One-way ANOVA between the groups for panels <bold>b</bold>–<bold>e</bold>. Source data for panels <bold>b</bold>–<bold>e</bold> are provided as a Source Data file.</p></caption><graphic id="d30e1313" xlink:href="41467_2020_16629_Fig6_HTML"></graphic></fig></p>
<p id="Par22">[<sup>3</sup>H]Epibatidine binding in brain largely reflects α4β2 receptors and was absent in cerebral cortex of α4 knockout mice<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Importantly, incubating cortical neurons with DFMO or transducing them with a lentivirus expressing SAT1 enhanced levels of [<sup>3</sup>H]epibatidine binding (Fig. <xref ref-type="fig" rid="Fig6">6d</xref>), indicating an increased α4β2 receptor assembly. To confirm polyamine regulation of neuronal α4β2, we transduced cortical neurons with α4-expressing and β2-expressing lentiviruses. Levels of [<sup>3</sup>H]epibatidine binding to the transduced neuronal membranes were ~20 times higher than untransduced neurons, and this was further increased with DFMO pretreatment (Fig. <xref ref-type="fig" rid="Fig6">6d</xref>). Importantly, neither DFMO preincubation nor SAT1 transduction altered binding sites for the GABA receptor ligand [<sup>3</sup>H]flunitrazepam (Fig. <xref ref-type="fig" rid="Fig6">6d</xref>). Taken together, these data show that polyamines regulate assembly of neuronal nAChR but not AMPA or GABA receptors.</p>
</sec>
<sec id="Sec8">
<title>Polyamines modulate nicotine-mediated neuroprotection</title>
<p id="Par23">Nicotine has well-established neuroprotective properties and can mitigate excitotoxicity in vivo<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> and in vitro<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. This neuroprotection is mediated both by α7<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> and α4β2 nAChRs<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. To assess the functional consequence of polyamine upregulation of receptor assembly, we asked whether this nicotine-mediated neuroprotection could be enhanced by reducing cellular polyamine levels. We induced excitotoxicity by challenging cultured neurons for one hour with glutamate (30 µM) and quantified cell survival and cytosolic cytochrome C (CytC), which is a trigger for apoptosis<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. We also surface-labeled α7 receptors with fluorescent α-Bgt. In line with previous reports, glutamate challenge induced excitotoxity and increased cytosolic CytC (Supplementary Fig. <xref ref-type="media" rid="MOESM1">7a–c</xref>). Co-application of 100 μM nicotine reduced excitotoxicity, but glutamate did not alter surface expression of α7 (Supplementary Fig. <xref ref-type="media" rid="MOESM1">7b, d</xref>). On the other hand, neurons pretreated with either DFMO or nicotine showed a three-fold increase in surface α-Bgt-binding sites (Supplementary Fig. <xref ref-type="media" rid="MOESM1">7a, d</xref>) and a concordant reduction of glutamate-induced CytC release (Fig. <xref ref-type="fig" rid="Fig6">6e</xref>; Supplementary Fig. <xref ref-type="media" rid="MOESM1">7c</xref>). Nicotine or DFMO preincubation also augmented nicotine-mediated protection from glutamate-mediated excitotoxic cell death (Fig. <xref ref-type="fig" rid="Fig6">6e</xref> and Supplementary Fig. <xref ref-type="media" rid="MOESM1">7b</xref>).</p>
<p id="Par24">To more directly link the neuroprotective effects of DFMO with nAChRs, we studied NACHO KO mice, which have dramatically reduced nAChR function in brain<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. We found that nicotine blunted glutamate-induced cell death in neurons from wild-type but not NACHO KO mice (Fig. <xref ref-type="fig" rid="Fig7">7a–c</xref>). Fitting with results from our rat cortical neuron experiments, we found that pre-treating wild-type mouse neurons with DFMO increased surface α-Bgt staining (Fig. <xref ref-type="fig" rid="Fig7">7e</xref>) and mitigated glutamate-induced increases in cytosolic CytC (Fig. <xref ref-type="fig" rid="Fig7">7d</xref>). By contrast, DFMO pre-treatment did not augment α-Bgt binding levels in NACHO KO neurons. Accordingly, DFMO preincubation did not confer subsequent nicotine-induced protection from excitotoxic neuronal death in NACHO KO neurons (Fig. <xref ref-type="fig" rid="Fig7">7c</xref>). Collectively, these experiments show that polyamines regulate functional assembly of nAChRs, which promotes neuroprotection in wild-type, but not NACHO KO neurons.<fig id="Fig7"><label>Fig. 7</label><caption><title>DFMO promotes nicotine-mediated neuroprotection in a NACHO-dependent fashion.</title><p><bold>a, b</bold> Images of cortical neurons (DIV 20) from wild-type (<bold>a</bold>) or NACHO KO (<bold>b</bold>) mice. As indicated, neurons were pretreated with DFMO (5 mM, 4th row) or and challenged with 30 μM glutamate (Glu, 2nd–4th row) in the absence (2nd row) or presence (3rd–4th row) of 100 μM nicotine. The cells were stained for MAP2 (left panel) and cytochrome-C (CytC middle panel) and surface α-Bgt647 (right panel). White squares indicate regions that are magnified. <bold>c</bold>–<bold>e</bold> Graphs quantify neuronal survival (<bold>c</bold>), CytC (<bold>d</bold>) and surface α-Bgt647 (<bold>e</bold>) (<italic>n</italic> = 6). Acute nicotine increases cell survival (<italic>p</italic> &lt; 1e<sup>−4</sup>) and reduces CytC mobilization (<italic>p</italic> = 0.0002) during glutamate toxicity in wild-type neurons, but not in NACHO KO neurons (<italic>p</italic> = 0.9). DFMO pre-treatment further promotes nicotine-mediated cell survival (<italic>p</italic> &lt; 1e<sup>−4</sup>) and reduces CytC mobilization (<italic>p</italic> = 0.0002) in wildtype neurons. DFMO significantly enhances surface α-Bgt647 labeling of wild-type (<italic>p</italic> &lt; 1e<sup>−4</sup>) but not of NACHO KO neurons (<italic>p</italic> = 0.9). **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001, n.s = not significant, one-way ANOVA between the groups. Data displayed as mean ± SD. Source data for panel <bold>c</bold>–<bold>e</bold> are provided as a Source Data file.</p></caption><graphic id="d30e1499" xlink:href="41467_2020_16629_Fig7_HTML"></graphic></fig></p>
</sec>
</sec>
<sec id="Sec9" sec-type="discussion">
<title>Discussion</title>
<p id="Par25">This study identifies an unexpected role for polyamines in controlling assembly of neuronal α4β2 and α7 receptors. Our genome-wide analysis found that SAT1 increases assembly of α4β2 receptors to a much greater extent than any other protein screened, including the nicotinic receptor chaperone NACHO. Polyamine-regulated assembly is specific for certain nAChRs, is distinct from other nAChR chaperone mechanisms, and requires negatively charged amino acids within the α4 or α7 cytosolic loop. Blocking polyamine synthesis with DFMO upregulates neuronal α4β2 and α7 surface levels and promotes nicotine-mediated neuroprotection, which provides a new angle for drug discovery.</p>
<p id="Par26">The biogenesis of pentameric nAChRs is a complex and tightly-regulated process<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Seminal studies in the 1980s found that nicotine and other orthosteric ligands upregulate brain nACh protein levels, and this likely participates in nicotine dependence<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup>. In <italic>C. elegans</italic>, Ric-3 is required for efficient assembly of worm nAChRs<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>; in mammalian brain, NACHO is required for α7<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> and many other nAChRs<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Additional proteins synergize with NACHO for assembly of specific mammalian nAChRs. Ric-3<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and certain Bcl-2 family proteins<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> work with NACHO to promote function of α7, whereas BARP, LAMP5, and SULT2B1 conspire with NACHO to enhance function of α6-containing receptors<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Our discovery of SAT1 regulation identifies the polyamine pathway as an additional controlling mechanism for α4β2 and α7 receptors.</p>
<p id="Par27">These multiple layers of nAChR regulation utilize distinct mechanisms. In the case of α7, NACHO mediates subunit oligomerization<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Subsequent regulation by nicotine, Ric-3, and Bcl-2 proteins synergizes with NACHO to promote protein folding, receptor surface expression, and channel function<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Nicotine and other orthosteric ligands promote assembly through α7’s ACh binding domain<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> whereas Bcl-2 proteins<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and polyamines engage the receptor cytosolic loop. However, polyamine regulation involves a distinct mechanism, as we find SAT1 augments receptor assembly atop NACHO, nicotinic ligand, Ric-3, or Bcl-2 family proteins.</p>
<p id="Par28">It is intriguing to ask why nAChRs—but not other receptors in the Cys-loop superfamily including 5-HT3 and GABA<sub>A</sub> receptors—require accessories for functional expression. One possibility is that multiple assembly mechanisms provide regulatory nodes for controlling nAChR function. NACHO transcription is upregulated by physiological stimuli<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>, and Bcl-2 family protein levels are dynamically-induced during developmental and pathological processes<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Furthermore, protein accessories may also determine nAChR cellular localization. The α6-containing nAChRs specifically concentrate at presynaptic terminals of specific monoaminergic neurons, and this may be enabled by the lysosomal protein, LAMP5, which displays a similar restricted distribution<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>.</p>
<p id="Par29">Polyamines are ubiquitous in biology and play multiple roles in cell growth, survival, and differentiation<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. In neurons, polyamines control gating of several important ion channels. Cytosolic polyamines confer inward rectification to certain potassium channels, AMPA receptors, and nAChRs<sup><xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR22">22</xref></sup>. Elegant biophysical studies showed that neuronal depolarization draws cytosolic polyamines into the channel pore, which precludes ion flow<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. This polyamine site is accessible to extracellular philanthotoxins<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, which have long polyamine tails that can engage the channel.</p>
<p id="Par30">Our studies decisively establish that regulation of α7 and α4β2 assembly by polyamines is distinct from their classical role in controlling ion channel gating. First, we find that SAT1 increases α4β2 and α7 function even when recorded at hyperpolarized potentials that preclude nAChR gating control by cellular polyamines<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> (Fig. <xref ref-type="fig" rid="Fig1">1c, d</xref>). Second, SAT1 promotes assembly of non-functional α4β2 receptors that cannot bind ACh (Fig. <xref ref-type="fig" rid="Fig3">3e–i</xref>). Third, extracellular philanthotoxin acutely blocks α4β2 receptor function but philanthotoxin does not affect receptor assembly (Fig. <xref ref-type="fig" rid="Fig5">5a–c</xref>). Fourth, chronic but not acute application of a cell-permeable polyamine analog, BenSpm, reverses the effects of SAT1 on α7 and α4β2 receptor assembly and function (Fig. <xref ref-type="fig" rid="Fig2">2d</xref>). Interestingly, we find that SAT1 does not augment function of α6-containing nAChRs. Taking advantage of this α-subunit specificity, our α6/α4 chimeras determine that polyamine regulation of channel assembly involves the α4 cytosolic loop. Again, this is distinct from the pore region that determines polyamine control of rectification.</p>
<p id="Par31">As α7 and α4β2 are the most abundant nAChRs in human brain and control diverse aspects synaptic signaling and plasticity, polyamine regulation of their assembly has important physiological and pathophysiological implications. Polyamine levels in neurons are dynamically regulated over both short-time and long-time scales. Acutely, synaptic transmission increases synthesis of polyamines, which modulate integrative neuronal properties by reducing AMPA receptor currents<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> and provide an excitability buffer by negatively regulating Na<sup>+</sup> channels<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Long-lasting changes in synaptic transmission associated with pathological processes such as epilepsy dramatically upregulate ODC1<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>, which our study predicts would downregulate nAChR assembly. Indeed, α4-containing nAChRs levels are decreased in piriform cortex of kindled mice<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>.</p>
<p id="Par32">Polyamines and nAChRs share compelling links to neuropsychiatric disorders. Numerous genetic, genomic, and biochemical studies identify alterations in the polyamine pathway in major depressive disorder and suicide<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. An SNP in the promoter region of SAT1 that reduces expression is associated with suicide in a French-Canadian founder population<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Postmortem studies find reduced SAT1 protein and mRNA levels in precentral gyrus and cortical frontal lobe<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. Also, polyamine levels increase during anxiety episodes, and this polyamine stress response pathway<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> could suppress nAChR assembly. Fitting with this, preclinical and early clinical studies suggest that α7 or α4β2 agonists can improve depressive behavior in animal models and in depressed patients<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>.</p>
<p id="Par33">Numerous observations also link polyamine and nAChR alterations with cognitive and neurodegenerative processes. Spermine synthase mutations cause Snyder-Robinson syndrome characterized by mental retardation and juvenile myoclonic epilepsy<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, and these central symptoms are also found in certain patients with mutations in α4 nAChR<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Interestingly, both SAT1 overexpression<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> and nicotine<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> protect animals from kainate-induced toxicity. Polyamine levels are elevated<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> and nAChR levels are reduced<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> in Alzheimer’s disease, which is best treated today with cholinesterase inhibitors that augment nAChR activity. Furthermore, DFMO<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> and nicotinic agonists<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> both mitigate neurotoxicity from neuronal ischemia. Our results that blocking ODC1 increases neuronal α4β2 and α7 and promotes nicotine-mediated neuroprotection provide a mechanistic link for these observations. As such, targeting this polyamine/nAChR assembly pathway provides a new neuropharmacological strategy.</p>
</sec>
<sec id="Sec10">
<title>Methods</title>
<sec id="Sec11">
<title>Genes and molecular biology and cell culture</title>
<p id="Par34">The following genes are studied here: (Human forms) CHRNA4 (NM_000744.6), CHRNB2 (NM_000748.2), CHRNA7 (NM_000746.5), CHRNA6 (NM_004198), CHRNB4 (NM_000750), TMEM35A or NACHO (NM_021637.2), Ric-3 (NM_024557.5), Bcl-X<sub>L</sub> (NM_138578.2), Mcl-1 (NM_021960.4), SAT1 (NM_002970.3), ODC1 (NM_002539); (mouse forms) 5HT-<sub>3</sub>A (NM_013561), AMD1 (NM_009665).</p>
<p id="Par35">Chimeric constructs used in this study, with residues in the parenthesis are: α6NT/α4 (α6<sub>1-239</sub>/α4<sub>243–628</sub>), α4NT/α6 (α4<sub>1–242</sub>/α6<sub>240–495</sub>), α6/α4loop (α6<sub>328–465</sub> exchanged to α4<sub>331–600</sub>), α4/α6loop (α4<sub>331–600</sub> exchanged to α6<sub>328–465</sub>), α7/α6loop (α7<sub>328–457</sub> exchanged to α6<sub>339–453</sub>). In brief, for α6NT/α4 chimera, α4<sub>243–628</sub> region and α6<sub>1–239</sub> was linearized and amplified with PCR. The primers for α6<sub>1–239</sub> contained complementary overhangs immediately upstream and downstream of amplified region. PCR products were ligated using In-Fusion HD Cloning Plus kit (Takara, 683910) in accordance with manufacturer’s protocol. All other chimeras were generated following similar strategy and were confirmed by sequencing. Site-directed mutagenesis was done with two complementary primer reactions (primer details provided in Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>), and all mutations were confirmed by sequencing. The α7-HA, β2-HA, and β4-HA constructs contained a PSGA linker and HA tag immediately following the C-terminal residue.</p>
<p id="Par36">HEK293T cells (ATCC® CRL-3216™) were cultured in DMEM medium supplemented with 10% FBS and 1 mM sodium pyruvate. Cells were seeded at 80-90% confluence and were transiently transfected using FuGENE®6 transfection reagents (Promega Corporation). All functional and expression assays in HEK293T cells were performed after 48–72 h incubation at 37 °C following transfection, unless stated otherwise.</p>
<p id="Par37">All animal experiments reported here were overseen and approved by an AAALAC accredited institutional review board. Primary cortical neurons were prepared from E18 rat cortex (supplied by BrainBits®) and E18 mice cortices from wild-type or NACHO knockout mice (TMEM35a<sup>tm1(KOMP)Vlcg</sup>)<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> (obtained from the laboratory’s vivarium). Cortices were dissociated using 10 U/mL papain (Worthington) digestion for 10 min, followed by trituration with a 10 mL glass pipette. Neurons were seeded at 15,000 cells per well (384-well plates) and maintained in NbActiv4® media (BrainBits®). Immunostaining or FLIPR assays were performed at DIV 20 or DIV 13, respectively, following 6 days incubation in nicotine (100 µM) or DFMO (5 mM) as indicated. For radioligand binding assays, neurons were transduced with SAT1 or α4 and β2 encoding lentiviruses (DIV 7) or treated with DFMO (DIV 14) and harvested on DIV 20. The lentiviral vectors encoding SAT1, α4 and β2 used a PGK promoter for transgene expression. The SAT1-expressing viral particles were packaged by Vigene Biosciences™, while the α4-expressing and β2-expressing viruses were packaged by VectorBuilder.</p>
</sec>
<sec id="Sec12">
<title>Broad cDNA library screen</title>
<p id="Par38">The cDNA library used for α4β2 screening was from the Broad Institute and contains 5943 cDNA clones. This genome-wide screen used a FLIPR assay on transfected HEK293T cells in 384-well plates. Each well was transfected with 60 ng of total cDNA with the following composition: α4:β2:single Broad gene (2:4:3). Transfections with NACHO (α4:β2:NACHO [2:4:3]) served as positive control.</p>
</sec>
<sec id="Sec13">
<title>FLIPR assay for agonist-evoked Ca<sup>2+</sup> influx</title>
<p id="Par39">High-throughput FLIPR assays were conducted using 384-well BioCoat (Corning) plates. Cells were washed briefly in assay buffer (HyClone™ HEPES-buffered saline [GE Life Sciences] comprising 149 mM NaCl, 4 mM KCl, 10 mM HEPES, and 5 mM glucose at pH 7.4 and 300 mOsm osmolality, supplemented with 2 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>) prior to Calcium5 dye (Molecular Devices) loading for 1 h at RT. Following removal of excess dye, plates were placed in the FLIPR Tetra (Molecular Devices) chamber, and fluorescent Ca<sup>2+</sup> signal was captured using ScreenWorks 4.0™ software (Molecular Devices).</p>
<p id="Par40">To obtain neuronal α7 mediated FLIPR responses, we used 5 μM PNU-12059615—a selective drug that attenuates receptor desensitization. Tetrodotoxin, or TTX (500 nM) was included in the assay buffer to inhibit spontaneous action potentials.</p>
</sec>
<sec id="Sec14">
<title>Immunofluorescent staining and image analysis</title>
<p id="Par41">HEK293T cells seeded on 384-well BioCoat plates (Corning) were incubated with primary antibody against HA tag—Dylight 650® (Invitrogen™) in culture media for 1 h at 37 °C. Cells were fixed with 4% PFA (in HyClone™ HEPES-buffered saline) for 60 min, and after washing, nuclei were stained with DAPI or NucBlue® reagent (Invitrogen™).</p>
<p id="Par42">For neurons, cells were fixed with 4% PFA for 1 h and then stained with fluorescent α-Bgt conjugates (1 μg/mL, AlexaFluor 647, Invitrogen™, B35450) or primary antibodies for 1 h. Then cells were simultaneous permeabilized and blocked in 0.2% Triton X-100 and 10% normal goat serum for 30 min. To label intracellular components, neurons were incubated in primary and secondary antibodies sequentially for 1 h each. Nuclei were stained with DAPI or NucBlue® reagent (Invitrogen™) prior to imaging.</p>
<p id="Par43">Primary antibodies used were: HA (Mouse, 1:500, Invitrogen™ 2-2.2.14) conjugated to DyLight 650, GluA1 N-terminal (Mouse, 1:250, Millipore-Sigma RH95), Cytochrome C (Mouse, 1:100, Invitrogen™ 7H8.2C12), MAP2 (Chicken, 1:1000, Millipore-Sigma AB15452). Secondary antibody used: goat anti-mouse IgG (H + L) AlexaFluor 488 (Invitrogen™, A-11001), goat anti-chicken IgY (H + L) AlexaFluor 555 (Invitrogen™, A-21437) at 1:1000 dilution.</p>
<p id="Par44">For quantification, images were acquired using Harmony™ high-content imaging software on an Opera Phenix™ screening instrument (PerkinElmer) with a ×20 objective. Data were further analyzed with the Columbus™ data storage and analysis system (PerkinElmer). Viable cells were identified from the DAPI signal (area &gt;30 μm<sup>2</sup> for HEK293T; area &gt;10 μm<sup>2</sup> for neurons). Cell perimeter was determined from the nuclear staining, and area of the cytoplasm was calculated based on the cytoplasmic region of interest. Average fluorescence intensity of wells was determined after subtracting the background signal, which was defined as anti-HA labeling of untransfected HEK293T cells or as α-Bgt647 labeling not displaced by 10 μM epibatidine.</p>
</sec>
<sec id="Sec15">
<title>Radioligand binding assays</title>
<p id="Par45">HEK293T cells or cortical neurons were harvested in 50 mM ice-cold TrisHCl buffer (pH 7.4). Cells were homogenized for 30 s using the T-25 Ultra-Turrax homogenizer (Ika) and total protein concentration of the homogenate was determined using the Pierce™ BCA Protein Assay Kit (Thermo Scientific). Cell homogenates were incubated with 10 nM [<sup>3</sup>H]epibatidine (for nAChR) or with 30 nM [<sup>3</sup>H]flunitrazepam (for GABA) in 96-well plates for 3 h at room temperature. Nonspecific binding was determined by co-incubation of the cell samples with 10 μM unlabeled epibatidine or 100 μM unlabeled flunitrazepam. Assays were terminated by filtration through polyethylenimine-treated 96-well Unifilter GF/B plates (PerkinElmer). Filter plates were washed with 500 mL TrisHCL buffer and then desiccated at 65 °C for 30 min. MicroScint-0 scintillant cocktail (50 μL; PerkinElmer) was added to each well and plates read with a TopCount NXT scintillation counter (PerkinElmer).</p>
</sec>
<sec id="Sec16">
<title>Electrophysiology</title>
<p id="Par46">HEK293T cells were seeded (1 million/well) on uncoated six-well plates and transfected with cDNA combinations (total 2 μg/well) using FuGENE®6 transfection reagent (Promega Corporation). eGFP plasmid (10% of total cDNA) identified transfected cells. After 24 h, cells were dissociated using CellStripper™ dissociation reagent (Corning) and re-seeded on 12 mm glass coverslips (40,000/well). Electrophysiological recordings were done 48 h after transfection using external solution composed of HyClone™ HEPES-buffered saline (149 mM NaCl, 4 mM KCl, 10 mM HEPES, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub> and 5 mM Glucose at pH 7.4; 300 mOsm osmolality). Intracellular solution contained (mM): 140 potassium gluconate, 10 HEPES, 4 Mg-ATP, 0.4 Na-GTP, and 0.6 EGTA (pH 7.3). To study most receptors, fast perfusion of compounds was achieved with the Perfusion Fast-Step system (Warner Instruments). To study α7 nAChRs, ultra-fast perfusion of compounds was achieved with a piezo-driven perfusion system and theta glass (Siskiyou) on to eGFP-expressing cells. The membrane holding potential was −70 mV. All recordings were performed at room temperature using an Axopatch 200B amplifier (Axon Instruments) and signals were filtered at 2 kHz and digitized at 10 kHz. For α7 nAChRs, signals were filtered at 10 kHz with a digitization rate of 50 kHz. Data acquisition and subsequent analysis were done with pClamp9 software (Axon Instruments).</p>
</sec>
<sec id="Sec17">
<title>Statistics</title>
<p id="Par47">Results are represented as mean ± SD unless stated otherwise. All FLIPR assay, immunostaining experiments and radioligand binding assay in HEK293T cells and rat neurons were replicated thrice. Significance analyses between two datasets were performed with nonparametric Mann–Whitney <italic>U</italic> test, while statistical analyses between three or more datasets used one-way ANOVA (GraphPad Prism, Carlsbad, CA). Significance level α = 0.05 was set.</p>
</sec>
<sec id="Sec18">
<title>Reporting summary</title>
<p id="Par48">Further information on research design is available in the <xref ref-type="media" rid="MOESM3">Nature Research Reporting Summary</xref> linked to this article.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec19">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2020_16629_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2020_16629_MOESM2_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2020_16629_MOESM3_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<app-group>
<app id="App1">
<sec id="Sec20">
<title>Source data</title>
<p id="Par51">
<media id="MOESM4" position="anchor" xlink:href="41467_2020_16629_MOESM4_ESM.xlsx"><caption><p>Source Data</p></caption></media>
</p>
</sec>
</app>
</app-group>
<fn-group>
<fn>
<p><bold>Peer review information</bold>
<italic>Nature Communications</italic> thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.</p>
</fn>
<fn>
<p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p><bold>Supplementary information</bold> is available for this paper at 10.1038/s41467-020-16629-3.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors are grateful to Wes Davini for his valuable inputs.</p>
</ack>
<notes notes-type="author-contribution">
<title>Author contributions</title>
<p>M.D. and M.L. performed cDNA library screening. J.A.M. conducted electrophysiology experiments. M.D. and H.Y. performed immunocytochemistry assays. M.D. conducted radioligand binding assays. D.K. and S.G. provided chimeric cDNA constructs. M.D. and D.S.B. wrote the manuscript. All authors contributed to the discussion and editing of the paper. D.S.B. supervised the project.</p>
</notes>
<notes notes-type="data-availability">
<title>Data availability</title>
<p>Data supporting the findings of this manuscript are available from the corresponding author upon reasonable request. A reporting summary for this Article is available as a Supplementary Information file. The source data underlying Figs. <xref ref-type="fig" rid="Fig1">1</xref>b, d; <xref ref-type="fig" rid="Fig2">2</xref>b–d; <xref ref-type="fig" rid="Fig3">3</xref>b, c, g, i; <xref ref-type="fig" rid="Fig5">5</xref>b, c, e; <xref ref-type="fig" rid="Fig6">6</xref>b–e; <xref ref-type="fig" rid="Fig7">7c–e</xref> and Supplementary Figs. <xref ref-type="media" rid="MOESM4">2b</xref>; <xref ref-type="media" rid="MOESM4">3b,</xref> c; <xref ref-type="media" rid="MOESM4">4b</xref>, c, f; <xref ref-type="media" rid="MOESM4">5</xref>d, e; <xref ref-type="media" rid="MOESM4">6b–d</xref> are provided in the Source Data File. Source data are provided with this paper.</p>
</notes>
<notes id="FPar1" notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par49">All contributing authors are full-time employees in Johnson and Johnson.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Role</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>Nicotinic receptors in the development and modulation of CNS synapses</article-title>
<source/>Neuron
          <year>1996</year>
<volume>16</volume>
<fpage>1077</fpage>
<lpage>1085</lpage>
<pub-id pub-id-type="pmid">8663984</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Clementi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Neuronal nicotinic receptors: from structure to pathology</article-title>
<source/>Prog. Neurobiol.
          <year>2004</year>
<volume>74</volume>
<fpage>363</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="pmid">15649582</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindstrom</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptors in health and disease</article-title>
<source/>Mol. Neurobiol.
          <year>1997</year>
<volume>15</volume>
<fpage>193</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="pmid">9396010</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hogg</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Raggenbass</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptors: from structure to brain function</article-title>
<source/>Rev. Physiol., Biochem. Pharmacol.
          <year>2003</year>
<volume>147</volume>
<fpage>1</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="pmid">12783266</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Novere</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Corringer</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Changeux</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences</article-title>
<source/>J. Neurobiol.
          <year>2002</year>
<volume>53</volume>
<fpage>447</fpage>
<lpage>456</lpage>
<pub-id pub-id-type="pmid">12436412</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picciotto</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Nicotine as a modulator of behavior: beyond the inverted U</article-title>
<source/>Trends Pharmacol. Sci.
          <year>2003</year>
<volume>24</volume>
<fpage>493</fpage>
<lpage>499</lpage>
<pub-id pub-id-type="pmid">12967775</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dineley</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Pandya</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Yakel</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Nicotinic ACh receptors as therapeutic targets in CNS disorders</article-title>
<source/>Trends Pharmacol. Sci.
          <year>2015</year>
<volume>36</volume>
<fpage>96</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">25639674</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurst</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rollema</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptors: from basic science to therapeutics</article-title>
<source/>Pharmacol. Therapeutics
          <year>2013</year>
<volume>137</volume>
<fpage>22</fpage>
<lpage>54</lpage>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor alpha7 subunit</article-title>
<source/>J. Neurochem.
          <year>1997</year>
<volume>68</volume>
<fpage>2140</fpage>
<lpage>2151</lpage>
<pub-id pub-id-type="pmid">9109542</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kassner</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>Differences in the fate of neuronal acetylcholine receptor protein expressed in neurons and stably transfected cells</article-title>
<source/>J. Neurobiol.
          <year>1997</year>
<volume>33</volume>
<fpage>968</fpage>
<lpage>982</lpage>
<pub-id pub-id-type="pmid">9407017</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain alpha7 nicotinic acetylcholine receptor assembly requires NACHO</article-title>
<source/>Neuron
          <year>2016</year>
<volume>89</volume>
<fpage>948</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="pmid">26875622</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matta</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NACHO mediates nicotinic acetylcholine receptor function throughout the brain</article-title>
<source/>Cell Rep.
          <year>2017</year>
<volume>19</volume>
<fpage>688</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="pmid">28445721</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>alpha6-Containing nicotinic acetylcholine receptor reconstitution involves mechanistically distinct accessory components</article-title>
<source/>Cell Rep.
          <year>2019</year>
<volume>26</volume>
<fpage>866</fpage>
<lpage>874 e863</lpage>
<pub-id pub-id-type="pmid">30673609</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millar</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>RIC‐3: a nicotinic acetylcholine receptor chaperone</article-title>
<source/>Br. J. Pharmacol.
          <year>2008</year>
<volume>153</volume>
<fpage>S177</fpage>
<lpage>S183</lpage>
<pub-id pub-id-type="pmid">18246096</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dawe</surname>
<given-names>GB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>alpha7 nicotinic acetylcholine receptor upregulation by anti-apoptotic Bcl-2 proteins</article-title>
<source/>Nat. Commun.
          <year>2019</year>
<volume>10</volume>
<fpage>2746</fpage>
<pub-id pub-id-type="pmid">31227712</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Changeux</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Nicotine addiction and nicotinic receptors: lessons from genetically modified mice</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2010</year>
<volume>11</volume>
<fpage>389</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="pmid">20485364</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller-Fleming</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Olin-Sandoval</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ralser</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Remaining mysteries of molecular biology: the role of polyamines in the cell</article-title>
<source/>J. Mol. Biol.
          <year>2015</year>
<volume>427</volume>
<fpage>3389</fpage>
<lpage>3406</lpage>
<pub-id pub-id-type="pmid">26156863</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pegg</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Casero</surname>
<given-names>RA</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Current status of the polyamine research field</article-title>
<source/>Methods Mol. Biol.
          <year>2011</year>
<volume>720</volume>
<fpage>3</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">21318864</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turecki</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The molecular bases of the suicidal brain</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2014</year>
<volume>15</volume>
<fpage>802</fpage>
<lpage>816</lpage>
<pub-id pub-id-type="pmid">25354482</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nichols</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Polyamines and potassium channels: a 25-year romance</article-title>
<source/>J. Biol. Chem.
          <year>2018</year>
<volume>293</volume>
<fpage>18779</fpage>
<lpage>18788</lpage>
<pub-id pub-id-type="pmid">30333230</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Interactions of polyamines with ion channels</article-title>
<source/>Biochemical J.
          <year>1997</year>
<volume>325</volume>
<fpage>289</fpage>
<lpage>297</lpage>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haghighi</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A molecular link between inward rectification and calcium permeability of neuronal nicotinic acetylcholine alpha3beta4 and alpha4beta2 receptors</article-title>
<source/>J. Neurosci.
          <year>2000</year>
<volume>20</volume>
<fpage>529</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">10632582</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muszynski</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Henley</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>DFMO reduces cortical infarct volume after middle cerebral artery occlusion in the rat</article-title>
<source/>J. Cereb. Blood Flow. Metab.
          <year>1993</year>
<volume>13</volume>
<fpage>1033</fpage>
<lpage>1037</lpage>
<pub-id pub-id-type="pmid">8408313</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A public genome-scale lentiviral expression library of human ORFs</article-title>
<source/>Nat. methods
          <year>2011</year>
<volume>8</volume>
<fpage>659</fpage>
<lpage>661</lpage>
<pub-id pub-id-type="pmid">21706014</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kachel</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Franzyk</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>IR</given-names>
</name>
</person-group>
<article-title>Block of nicotinic acetylcholine receptors by philanthotoxins is strongly dependent on their subunit composition</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>38116</fpage>
<pub-id pub-id-type="pmid">27901080</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bewley</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structures of wild-type and mutant human spermidine/spermine N1-acetyltransferase, a potential therapeutic drug target</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>2006</year>
<volume>103</volume>
<fpage>2063</fpage>
<lpage>2068</lpage>
<pub-id pub-id-type="pmid">16455797</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerner</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Meyskens</surname>
<given-names>FL</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Polyamines and cancer: old molecules, new understanding</article-title>
<source/>Nat. Rev. Cancer
          <year>2004</year>
<volume>4</volume>
<fpage>781</fpage>
<lpage>792</lpage>
<pub-id pub-id-type="pmid">15510159</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prince</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Sine</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Epibatidine binds with unique site and state selectivity to muscle nicotinic acetylcholine receptors</article-title>
<source/>J. Biol. Chem.
          <year>1998</year>
<volume>273</volume>
<fpage>7843</fpage>
<lpage>7849</lpage>
<pub-id pub-id-type="pmid">9525877</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mandal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Orjalo</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>2169</fpage>
<lpage>2174</lpage>
<pub-id pub-id-type="pmid">23345430</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morales-Perez</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Noviello</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hibbs</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>X-ray structure of the human alpha4beta2 nicotinic receptor</article-title>
<source/>Nature
          <year>2016</year>
<volume>538</volume>
<fpage>411</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="pmid">27698419</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stokes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Treinin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Papke</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Looking below the surface of nicotinic acetylcholine receptors</article-title>
<source/>Trends Pharmacol. Sci.
          <year>2015</year>
<volume>36</volume>
<fpage>514</fpage>
<lpage>523</lpage>
<pub-id pub-id-type="pmid">26067101</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tikhonov</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Usherwood</surname>
<given-names>PN</given-names>
</name>
</person-group>
<article-title>Modeling noncompetitive antagonism of a nicotinic acetylcholine receptor</article-title>
<source/>Biophys. J.
          <year>2004</year>
<volume>87</volume>
<fpage>159</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">15240454</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>DK</given-names>
</name>
</person-group>
<article-title>Nicotinic acetylcholine receptors containing alpha 7 subunits on rat cortical neurons do not undergo long-lasting inactivation even when up-regulated by chronic nicotine exposure</article-title>
<source/>J. Neurochem.
          <year>2001</year>
<volume>78</volume>
<fpage>1367</fpage>
<lpage>1378</lpage>
<pub-id pub-id-type="pmid">11579145</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurst</surname>
<given-names>RS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization</article-title>
<source/>J. Neurosci.
          <year>2005</year>
<volume>25</volume>
<fpage>4396</fpage>
<lpage>4405</lpage>
<pub-id pub-id-type="pmid">15858066</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marubio</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced antinociception in mice lacking neuronal nicotinic receptor subunits</article-title>
<source/>Nature
          <year>1999</year>
<volume>398</volume>
<fpage>805</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="pmid">10235262</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borlongan</surname>
<given-names>CV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(–)-nicotine protects against systemic kainic acid-induced excitotoxic effects</article-title>
<source/>Exp. Neurol.
          <year>1995</year>
<volume>136</volume>
<fpage>261</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="pmid">7498416</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akaike</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yokota</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimohama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity</article-title>
<source/>Brain Res.
          <year>1994</year>
<volume>644</volume>
<fpage>181</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="pmid">7519524</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Maus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Desagher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Glowinski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Premont</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity</article-title>
<source/>Neuroreport
          <year>1994</year>
<volume>5</volume>
<fpage>1977</fpage>
<lpage>1980</lpage>
<pub-id pub-id-type="pmid">7841389</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dajas-Bailador</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Wonnacott</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism</article-title>
<source/>Neuropharmacology
          <year>2000</year>
<volume>39</volume>
<fpage>2799</fpage>
<lpage>2807</lpage>
<pub-id pub-id-type="pmid">11044750</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hejmadi</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Dajas-Bailador</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Barns</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wonnacott</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes</article-title>
<source/>Mol. Cell. Neurosci.
          <year>2003</year>
<volume>24</volume>
<fpage>779</fpage>
<lpage>786</lpage>
<pub-id pub-id-type="pmid">14664825</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kharbanda</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>1997</year>
<volume>94</volume>
<fpage>6939</fpage>
<lpage>6942</lpage>
<pub-id pub-id-type="pmid">9192670</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orrenius</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhivotovsky</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Cardiolipin oxidation sets cytochrome c free</article-title>
<source/>Nat. Chem. Biol.
          <year>2005</year>
<volume>1</volume>
<fpage>188</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="pmid">16408030</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>WN</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>Ion-channel assembly</article-title>
<source/>Trends Neurosci.
          <year>1995</year>
<volume>18</volume>
<fpage>280</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="pmid">7571003</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Kellar</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo</article-title>
<source/>Science
          <year>1983</year>
<volume>220</volume>
<fpage>214</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">6828889</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lester</surname>
<given-names>HA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry</article-title>
<source/>Implic. Drug Discov. AAPS J.
          <year>2009</year>
<volume>11</volume>
<fpage>167</fpage>
<lpage>177</lpage>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halevi</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The C. elegans ric‐3 gene is required for maturation of nicotinic acetylcholine receptors</article-title>
<source/>EMBO J.
          <year>2002</year>
<volume>21</volume>
<fpage>1012</fpage>
<lpage>1020</lpage>
<pub-id pub-id-type="pmid">11867529</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tran</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Georgieff</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Engeland</surname>
<given-names>WC</given-names>
</name>
</person-group>
<article-title>Sodium depletion increases sympathetic neurite outgrowth and expression of a novel TMEM35 gene-derived protein (TUF1) in the rat adrenal zona glomerulosa</article-title>
<source/>Endocrinology
          <year>2010</year>
<volume>151</volume>
<fpage>4852</fpage>
<lpage>4860</lpage>
<pub-id pub-id-type="pmid">20685870</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youle</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Strasser</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The BCL-2 protein family: opposing activities that mediate cell death</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2008</year>
<volume>9</volume>
<fpage>47</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">18097445</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiveron</surname>
<given-names>MC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LAMP5 fine-tunes GABAergic synaptic transmission in defined circuits of the mouse brain</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<fpage>e0157052</fpage>
<pub-id pub-id-type="pmid">27272053</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stromgaard</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Solid-phase synthesis and biological evaluation of a combinatorial library of philanthotoxin analogues</article-title>
<source/>J. Med. Chem.
          <year>2000</year>
<volume>43</volume>
<fpage>4526</fpage>
<lpage>4533</lpage>
<pub-id pub-id-type="pmid">11087577</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aizenman</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Munoz-Elias</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cline</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Visually driven modulation of glutamatergic synaptic transmission is mediated by the regulation of intracellular polyamines</article-title>
<source/>Neuron
          <year>2002</year>
<volume>34</volume>
<fpage>623</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="pmid">12062045</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleidervish</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Libman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gutnick</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Endogenous polyamines regulate cortical neuronal excitability by blocking voltage-gated Na+ channels</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>2008</year>
<volume>105</volume>
<fpage>18994</fpage>
<lpage>18999</lpage>
<pub-id pub-id-type="pmid">19020082</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herberg</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>de Belleroche</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Mintz</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Ornithine decarboxylase induction and polyamine synthesis in the kindling of seizures: the effect of alpha-difluoromethylornithine</article-title>
<source/>Epilepsy Res.
          <year>1992</year>
<volume>11</volume>
<fpage>3</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">1563337</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takechi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Suemaru</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kiyoi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The alpha4beta2 nicotinic acetylcholine receptor modulates autism-like behavioral and motor abnormalities in pentylenetetrazol-kindled mice</article-title>
<source/>Eur. J. Pharmacol.
          <year>2016</year>
<volume>775</volume>
<fpage>57</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">26868186</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Limon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mamdani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hjelm</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Vawter</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Targets of polyamine dysregulation in major depression and suicide: Activity-dependent feedback, excitability, and neurotransmission</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2016</year>
<volume>66</volume>
<fpage>80</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">27108532</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sequeira</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Implication of SSAT by gene expression and genetic variation in suicide and major depression</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2006</year>
<volume>63</volume>
<fpage>35</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">16389195</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandelman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Newhouse</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>WD</given-names>
</name>
</person-group>
<article-title>Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2018</year>
<volume>84</volume>
<fpage>289</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="pmid">28859996</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peron</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Snyder-Robinson syndrome: a novel nonsense mutation in spermine synthase and expansion of the phenotype</article-title>
<source/>Am. J. Med. Genet. A
          <year>2013</year>
<volume>161A</volume>
<fpage>2316</fpage>
<lpage>2320</lpage>
<pub-id pub-id-type="pmid">23897707</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghasemi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hadipour-Niktarash</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Pathologic role of neuronal nicotinic acetylcholine receptors in epileptic disorders: implication for pharmacological interventions</article-title>
<source/>Rev. Neurosci.
          <year>2015</year>
<volume>26</volume>
<fpage>199</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="pmid">25565544</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaasinen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Koistinaho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alhonen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Janne</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Overexpression of spermidine/spermine N-acetyltransferase in transgenic mice protects the animals from kainate-induced toxicity</article-title>
<source/>Eur. J. Neurosci.
          <year>2000</year>
<volume>12</volume>
<fpage>540</fpage>
<lpage>548</lpage>
<pub-id pub-id-type="pmid">10712633</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications</article-title>
<source/>Biol. Psychiatry
          <year>2001</year>
<volume>49</volume>
<fpage>200</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">11230871</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>